Financial News

Nicox: Third Quarter 2019 Business Update and Financial Highlights

  • Positive topline results from Dolomites Phase 2 clinical trial of NCX 470 in glaucoma
  • VYZULTA prescriptions exceeded 3,000 per week for the first time1
  • Q3 2019 net revenue of €0.5 million

Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a Q3 2019 business update and financial highlights,

Read more

Nicox Amends Bond Financing Agreement with Kreos and Draws Down Additional €4 Million

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its bond financing agreement with Kreos Capital and drawn down an additional €4 million of debt under the bond financing. Nicox may now draw down a further €3 million or €8 million on December 31, 2019, subject to notice to Kreos by December 16,

Read more

Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost

  • NCX 470 met the primary endpoint of non-inferiority and also demonstrated superiority to latanoprost, the U.S. market leader in prostaglandin analog prescriptions, in multiple pre-specified analyses
  • Intraocular pressure (IOP) lowering effect from baseline of NCX 470 was 7.6 to 9.8 mmHg
  • All doses of NCX 470 were well tolerated with no drug-related serious adverse events

Sophia Antipolis,

Read more
More news
Press releases
More press releases